Seidman A D, Norton L, Reichman B S, Crown J P, Yao T J, Hakes T B, Lebwohl D E, Gilewski T A, Hudis C A, Surbone A
Memorial Sloan-Kettering Cancer Center, New York, NY 10021.
Oncology. 1994 Oct;51 Suppl 1:33-9. doi: 10.1159/000227414.
We treated 28 patients who had no prior chemotherapy for stage IV breast cancer and 51 patients with extensive prior exposure to other chemotherapeutic agents with a 24-hour infusion of Taxol (paclitaxel) as a single agent. Prophylactic recombinant human granulocyte colony-stimulating factor was administered routinely to ameliorate the anticipated dose-limiting toxicity of neutropenia. Nonhematologic toxicity was mild to moderate in most cases. Taxol was more active in patients with chemotherapy-naive stage IV disease, but activity was also observed in extensively treated patients as well. There is a strong clinical suggestion of at least partial noncross-resistance with doxorubicin. Taxol is a very promising agent for the treatment of metastatic breast cancer; its optimal application in this disease will be the subject of future trials.
我们对28例未曾接受过化疗的IV期乳腺癌患者以及51例曾广泛接触过其他化疗药物的患者进行了治疗，采用紫杉醇单药24小时静脉输注。常规给予预防性重组人粒细胞集落刺激因子以减轻预期的中性粒细胞减少剂量限制性毒性。在大多数情况下，非血液学毒性为轻度至中度。紫杉醇在未接受过化疗的IV期疾病患者中活性更高，但在接受过广泛治疗的患者中也观察到了活性。有强有力的临床证据表明其与阿霉素至少存在部分非交叉耐药性。紫杉醇是治疗转移性乳腺癌非常有前景的药物；其在该疾病中的最佳应用将是未来试验的主题。
